BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30231368)

  • 1. Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.
    Perrot A; Corre J; Avet-Loiseau H
    Am Soc Clin Oncol Educ Book; 2018 May; 38():675-680. PubMed ID: 30231368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic stratification of multiple myeloma treated with novel agents.
    Jiang A; Reece D; Chang H
    Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
    Lannes R; Samur M; Perrot A; Mazzotti C; Divoux M; Cazaubiel T; Leleu X; Schavgoulidze A; Chretien ML; Manier S; Adiko D; Orsini-Piocelle F; Lifermann F; Brechignac S; Gastaud L; Bouscary D; Macro M; Cleynen A; Mohty M; Munshi N; Corre J; Avet-Loiseau H
    J Clin Oncol; 2023 Mar; 41(9):1695-1702. PubMed ID: 36343306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
    Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
    Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomics of Multiple Myeloma.
    Robiou du Pont S; Cleynen A; Fontan C; Attal M; Munshi N; Corre J; Avet-Loiseau H
    J Clin Oncol; 2017 Mar; 35(9):963-967. PubMed ID: 28297630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytogenetic abnormalities in high-risk multiple myeloma].
    Ishida T
    Nihon Rinsho; 2015 Jan; 73(1):28-32. PubMed ID: 25626299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of chromosomal aberrations in multiple myeloma.
    Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
    J Intern Med; 2011 Feb; 269(2):137-47. PubMed ID: 21158983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
    Vincent Rajkumar S
    Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple Myeloma Genomics: A Systematic Review.
    Weaver CJ; Tariman JD
    Semin Oncol Nurs; 2017 Aug; 33(3):237-253. PubMed ID: 28729121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
    Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
    Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
    Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
    J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal Evolution in Multiple Myeloma.
    Fakhri B; Vij R
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
    Cazaubiel T; Leleu X; Perrot A; Manier S; Buisson L; Maheo S; Do Souto Ferreira L; Lannes R; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Schavgoulidze A; Avet-Loiseau H; Corre J
    Blood; 2022 Apr; 139(17):2666-2672. PubMed ID: 35171994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of genomics on the management of myeloma.
    Corre J; Avet-Loiseau H
    J Natl Compr Canc Netw; 2011 Oct; 9(10):1200-6. PubMed ID: 21975916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.